norfloxacin has been researched along with Sepsis in 15 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 9.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 5.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD)." | 1.72 | Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. ( Ahmadi, F; Garg, AX; Kim, RB; Knoll, GA; Muanda, FT; Silverman, MS; Sontrop, JM; Sood, MM; Weir, MA; Yoo, E, 2022) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "Pefloxacin was combined with an aminoglycoside in 13 cases and with rifampicin in 1 case." | 1.27 | [Treatment of septicemia and endocarditis with pefloxacine. 15 cases]. ( Bauchet, J; Pangon, B; Regnier, B; Rouveix, E; Vachon, F; Wolff, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Muanda, FT | 1 |
| Sood, MM | 1 |
| Weir, MA | 1 |
| Sontrop, JM | 1 |
| Ahmadi, F | 1 |
| Yoo, E | 1 |
| Kim, RB | 1 |
| Silverman, MS | 1 |
| Knoll, GA | 1 |
| Garg, AX | 1 |
| Sun, ZL | 1 |
| Sun, SC | 1 |
| He, JM | 1 |
| Lan, JE | 1 |
| Gibbons, S | 1 |
| Mu, Q | 1 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Díaz-De-Alba, P | 1 |
| Docobo-Perez, F | 1 |
| Rodríguez-Martínez, JM | 1 |
| Pascual, Á | 1 |
| Orogade, AA | 1 |
| Akuse, RM | 1 |
| Ghadage, DP | 1 |
| Bal, AM | 1 |
| Brodsky, A | 1 |
| Melero, M | 1 |
| Vay, C | 1 |
| Shah, PM | 1 |
| Classen, DC | 1 |
| Burke, JP | 1 |
| Ford, CD | 1 |
| Evershed, S | 1 |
| Aloia, MR | 1 |
| Wilfahrt, JK | 1 |
| Elliott, JA | 1 |
| Murray, BE | 1 |
| Wolff, M | 1 |
| Pangon, B | 1 |
| Regnier, B | 1 |
| Rouveix, E | 1 |
| Bauchet, J | 1 |
| Vachon, F | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Winston, DJ | 1 |
| Ho, WG | 1 |
| Champlin, RE | 1 |
| Karp, J | 1 |
| Bartlett, J | 1 |
| Finley, RS | 1 |
| Joshi, JH | 1 |
| Talbot, G | 1 |
| Levitt, L | 1 |
| Deresinski, S | 1 |
| Schmeiser, T | 1 |
| Kurrle, E | 1 |
| Arnold, R | 1 |
| Wiesneth, M | 1 |
| Bunjes, D | 1 |
| Hertenstein, B | 1 |
| Kern, W | 1 |
| Heit, W | 1 |
| Heimpel, H | 1 |
| Weinstein, MP | 1 |
| Chomarat, M | 1 |
| Joulie, V | 1 |
| Fournier, G | 1 |
| Bouletreau, P | 1 |
| Flandrois, JP | 1 |
1 review available for norfloxacin and Sepsis
| Article | Year |
|---|---|
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
2 trials available for norfloxacin and Sepsis
| Article | Year |
|---|---|
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Combinations; Drug Therapy, Com | 1987 |
12 other studies available for norfloxacin and Sepsis
| Article | Year |
|---|---|
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Death, Sudden, Cardia | 2022 |
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, | 2020 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Changing patterns in sensitivity of causative organisms of septicaemia in children: the need for quinolones.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Gr | 2004 |
Antibiotic susceptibility pattern of Salmonella worthington isolated from neonates--a retrospective study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Chloramphenicol; Ciprofloxacin; | 2002 |
[Methicillin-resistant Staphylococcus aureus infection in neutropenic patients during norfloxacin prophylaxis].
Topics: Adult; Fatal Outcome; Female; Humans; Immunocompromised Host; Methicillin Resistance; Middle Aged; N | 1992 |
Oral antibiotic prophylaxis in patients with hematological diseases.
Topics: Ciprofloxacin; Humans; Norfloxacin; Sepsis; Staphylococcal Infections | 1991 |
Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Drug Re | 1990 |
[Treatment of septicemia and endocarditis with pefloxacine. 15 cases].
Topics: Adult; Aged; Anti-Infective Agents; Child; Drug Resistance, Microbial; Endocarditis, Bacterial; Fema | 1986 |
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Female; Human | 1988 |
Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.
Topics: Anti-Bacterial Agents; Bacteria; Cefotaxime; Ceftazidime; Enoxacin; Fluoroquinolones; Humans; Imipen | 1988 |
[Pharmacokinetic study of pefloxacin in 37 hospital patients under resuscitation].
Topics: Humans; Intensive Care Units; Kinetics; Meningitis; Norfloxacin; Pefloxacin; Pneumonia; Risk; Sepsis | 1985 |